C. diff Risk


Oral Bioavailability


Approximate Cost



600 mg IV q12h

MRSA bloodstream infections/endocarditis may require higher dosing and should only be undertaken with Infectious Diseases or Antimicrobial Stewardship Program input.

≥ 2months of age and < 2 years of age> 2 years and < 18 years of age8 mg/kg/dose IV Q8H< 33kg: 12 mg/kg/dose IV Q8H
> 33kg: 400 mg IV Q8H or 600 mg IV Q12H

CrCl < 50 mL/min/1.73m²Data is insufficient to provide appropriate dose adjustment

Infectious Diseases consultation required for use, per policy HS1444

General Information

  • GI effects

  • Hypersensitivity reactions

  • C. difficile

  • Generally well-tolerated


  • Cr weekly


  • Hypersensitivity

  • Diarrhea,

  • Other GI effects

  • Complicated skin/skin structure infections*

  • Community-acquired bacterial pneumonia*

  • Salvage for sustained MRSA bacteremia/endocarditis*

  • Must meet the following criteria for use:

  • MRSA is highly suspected or documented AND vancomycin is not an option

  • MRSA with a vancomycin MIC ≥ 2

  • Sustained difficulty in achieving appropriate vancomycin levels despite clinical pharmacy assistance with pharmacokinetics or where a vancomycin continuous infusion is not an option.

  • Treatment of mixed infections, requires documentation of susceptibility

  • Selected over vancomycin in patients with renal failure solely as a reason to avoid vancomycin

  • Selected solely for convenience

Ceftaroline is FDA-approved for treatment of skin/skin structure infections (including cases caused by MRSA) and community-acquired pneumonia (including cases caused by penicillinresistant S. pneumoniae).

While there are animal models and case reports of successful use of ceftaroline for the treatment of osteomyelitis, bacteremia, and endocarditis, ceftaroline is not yet FDA-approved for these indications.